Trial · NCT04798612
Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression
NCT04798612, Phase 2, Unknown, Zealand University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression. Trials, record NCT04798612. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04798612
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression
- NCT number
- NCT04798612
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 68 participants, estimated
- Lead sponsor
- Zealand University Hospital
- Conditions
- Colon Cancer
- Interventions
- Pegasys, Saline
- First posted
- 2021-03-15
- Last updated
- 2023-08-18
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Flow-analysis of lymphocytic subpopulations in blood | Change between day of surgery (day 7-14 after first treatment) and postoperative day 1. | Change in CD3, CD4, and CD8 between intervention and placebo groups |
| Primary | T-cell infiltration in tumor | Day of surgery (day 7-14 after first treatment) | Difference in CD3, CD4 and CD8 T-cell infiltration between intervention and placebo groups |
| Secondary | Quality of recovery (QoR-15) | Third postoperative day and postoperative day 12-16 | Difference in QoR-15 between intervention and placebo groups |
| Secondary | Multiplex gene assay - NanoString Pan Cancer 360 IO panel analysis in blood and resected tumor | Day of first treatment (Day 0) and day of surgery (day 7-14 after first treatment) | Difference in gene expressions between intervention and placebo groups |
| Secondary | cfDNA analysis in blood | Day of first treatment (Day 0), day of surgery (day 7-14 after first treatment), postoperative day 2, postoperative day 12-16, and postoperative day 28-32. | Difference between intervention and placebo groups |
| Secondary | Multiplex gene assay - NanoString Pan Cancer 360 IO panel analysis of tumor biopsy and resected specimen | Day of standard endoscopic biopsy (Day -7-14 before treatment) and day of surgery (day 7-14 after first treatment) | Difference in gene expressions in tumor biopsies and resected specimen between intervention and placebo groups |
| Secondary | CRP and neutrophil/lymphocyte ratio | Day of surgery (day 7-14 after first treatment) | Difference in CRP and neutrophil/lymphocyte ratio between intervention and placebo groups |
| Secondary | Immunological and inflammatory cytokines and interleukins | Day of surgery (day 7-14 after first treatment) and postoperative day 1. | Difference between intervention and placebo groups |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04798612
GET https://conductscience.org/api/trials/v1/NCT04798612/registered